

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4757844/publications.pdf Version: 2024-02-01

		623734	752698
20	1,162	14	20
papers	citations	h-index	g-index
21 all docs	21 docs citations	21 times ranked	2352 citing authors

YLANCAL

#	Article	IF	CITATIONS
1	The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι. Proceedings of the United States of America, 2021, 118, .	7.1	317
2	Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. Immunity, 2020, 53, 1315-1330.e9.	14.3	215
3	Long noncoding RNA NRON contributes to HIV-1 latency by specifically inducing tat protein degradation. Nature Communications, 2016, 7, 11730.	12.8	134
4	TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb. ELife, 2019, 8, .	6.0	71
5	Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. Signal Transduction and Targeted Therapy, 2021, 6, 420.	17.1	46
6	Nonsteroidal Anti-inflammatory Drugs Potently Inhibit the Replication of Zika Viruses by Inducing the Degradation of AXL. Journal of Virology, 2018, 92, .	3.4	44
7	HIV-1 functional cure: will the dream come true?. BMC Medicine, 2015, 13, 284.	5.5	39
8	Histone chaperone CAFâ€1 promotes HIVâ€1 latency by leading the formation of phaseâ€separated suppressive nuclear bodies. EMBO Journal, 2021, 40, e106632.	7.8	27
9	USP49 potently stabilizes APOBEC3G protein by removing ubiquitin and inhibits HIV-1 replication. ELife, 2019, 8, .	6.0	27
10	Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency. Molecular Therapy, 2016, 24, 1528-1537.	8.2	23
11	Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques. Cellular and Molecular Immunology, 2021, 18, 1058-1060.	10.5	23
12	Non-coding RNAs and retroviruses. Retrovirology, 2018, 15, 20.	2.0	22
13	CUL7 E3 Ubiquitin Ligase Mediates the Degradation of Activation-Induced Cytidine Deaminase and Regulates the Ig Class Switch Recombination in B Lymphocytes. Journal of Immunology, 2019, 203, 269-281.	0.8	19
14	A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2. Cell Reports, 2022, 38, 110256.	6.4	19
15	Adenosine deaminase acting on RNA-1 (ADAR1) inhibits hepatitis B virus (HBV) replication by enhancing microRNA-122 processing. Journal of Biological Chemistry, 2019, 294, 14043-14054.	3.4	18
16	Lovastatin Inhibits HIV-1-Induced MHC-I Downregulation by Targeting Nef–AP-1 Complex Formation: A New Strategy to Boost Immune Eradication of HIV-1 Infected Cells. Frontiers in Immunology, 2019, 10, 2151.	4.8	12
17	CBX4 contributes to HIVâ€l latency by forming phaseâ€separated nuclear bodies and SUMOylating EZH2. EMBO Reports, 2022, 23,	4.5	12
18	PIWIL4 Maintains HIV-1 Latency by Enforcing Epigenetically Suppressive Modifications on the 5′ Long Terminal Repeat. Journal of Virology, 2020, 94, .	3.4	8

Χιανςαι

#	Article	IF	CITATIONS
19	Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L. Frontiers in Microbiology, 2022, 13, 884034.	3.5	8
20	Brd4 Regulates the Homeostasis of CD8+ T-Lymphocytes and Their Proliferation in Response to Antigen Stimulation. Frontiers in Immunology, 2021, 12, 728082.	4.8	3